Allergan rose$. 61 or. 5 percent, to $127.48. Baxter International Inc. fell$. 02 or percent, to $67.55. Boston Scientific Corp. fell$. 07 or. 5 percent, to $13.48.» Read More
Jeffrey Shuren, director of the FDA's medical device division, said. The FDA plans to phase in the UDI system over several years, focusing first on medical devices that carry the greatest risk to patients such as pacemakers, defibrillators, heart pumps and artificial joints.
The FDA will enter the unique device identifier, or UDI codes, into a database that the agency will maintian as a publicly searchable reference catalogue. The FDA plans to phase in the UDI system, focusing first on medical devices that carry the greatest risk to patients such as pacemakers, defibrillators, heart pumps and artificial joints.
Sept 20- Becton Dickinson and Co said it may have to pay up to $340 million after a federal jury found the medical device maker guilty of attempting to monopolize the safety syringe market through deceptive practices. The jury in a Texas district court awarded $113.5 million to safety syringes maker Retractable Technologies Inc, which filed the lawsuit.
NEW YORK, Sept 19- Swiss drugmaker Roche Holding AG has decided against trying to sell its blood glucose meter business, according to two people familiar with the matter. At least one other large drugmaker, Bayer AG, also scrapped plans to sell a diabetes device unit this year.
Sept 19- Medical device maker Covidien Plc said it would cut costs by outsourcing services to low-cost locations and consolidating manufacturing and distribution centers. The company said it expects to record related charges of about $350 million to $450 million, most of which will be incurred by the end of fiscal 2018..
LONDON, Sept 19- A 90- year-old helium reservoir in Texas could shut down next month causing disruptions and raising costs for makers of high-tech products from MRI scanners to semiconductors and threaten medical treatments and research.
**LAKELAND INDUSTRIES INC, $5.70, up 37 pct. The safety gear retailer's second-quarter earnings more than doubled to $4.2 million, or 74 cents per share, helped by higher revenue from the United States and China and lower operating expenses.
*Surprising trial results lead to rethinking of depression. *Disorder now seen as cluster of distinct conditions. LONDON, Sept 9- As Susan sits chatting to a nurse in a London clinic, a light tapping sound by her head signals that parts of her brain are being zapped by thousands of tiny electro-magnetic pulses from a machine plugged into the wall.
Pharmaceutical and biotech stocks have outperformed markets this year, and with J&J's second-quarter earnings beat, investors may hope earnings will push stocks even higher.
Americans accustomed to immediate access to the newest technology may be shocked to find that is not the case when it comes to devices that treat ailing hearts.
Keith Smith, Co-founder, Managing Partner at the Surgery Center of Oklahoma says that all funds are channeled to patient care, helping his team deliver quality healthcare and low costs.
Most robotic surgery takes place without a hitch, but a growing number of complaints and lawsuits allege complications and even deaths from Intuitive Surgical's da Vinci device.
If the critics of robotic surgery are right—that safety is an issue—how is that it was performed on 450,000 people last year? The answer may lie in one word: Marketing.
The number of complications from robot-assisted surgery using Intuitive Surgical's da Vinci robot are underreported, allege critics of the procedure, fanning the controversy around the company's pioneering product.
Intuitive Surgical's da Vinci robot was once hailed as a revolution in the operating room, but as more reports of complications have come to light, the da Vinci debate is heating up.
Like all computers, Intuitive Surgical's da Vinci robot can malfunction during surgery. A range of results have been reported by surgeons.
In recent years, as the surgical robot's popularity has grown, so have questions and concerns about its safety, training and the aggressiveness of its marketing.
Containing health care costs, promoting innovation and the treatment of deadly diseases are among the biggest challenges the U.S. faces, Johnson and Johnson CEO Alex Gorsky said on Thursday.
Irish drugmaker Elan has sweetened the terms on offer to shareholders under its $3.25 billion disposal plan, as it aims to stave off an approach for the company from U.S. investment firm Royalty Pharma.
A sharp and surprisingly persistent slowdown in the growth of health care costs is helping to narrow the federal deficit, leaving budget experts trying to figure out whether the trend will last.